์ฝ˜ํ…์ธ ๋กœ ๊ฑด๋„ˆ๋›ฐ๊ธฐ
Merck

T0535

Tolfenamic acid

NSAID

๋™์˜์–ด(๋“ค):

2 (3-Chloro-2-methylanilino)benzoic acid, 2-([3-Chloro-2-methylphenyl]amino)benzoic acid

์กฐ์ง ๋ฐ ๊ณ„์•ฝ ๊ฐ€๊ฒฉ์„ ๋ณด๋ ค๋ฉด ๋กœ๊ทธ์ธ๋ฅผ ํด๋ฆญํ•ฉ๋‹ˆ๋‹ค.

ํฌ๊ธฐ ์„ ํƒ


์ œํ’ˆ์ •๋ณด (DICE ๋ฐฐ์†ก ์‹œ ๋น„์šฉ ๋ณ„๋„)

์‹คํ—˜์‹(Hill ํ‘œ๊ธฐ๋ฒ•):
C14H12ClNO2
CAS ๋ฒˆํ˜ธ:
Molecular Weight:
261.70
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352202
EC Number:
237-264-3
MDL number:
๊ธฐ์ˆ  ์„œ๋น„์Šค
๋„์›€์ด ํ•„์š”ํ•˜์‹ ๊ฐ€์š”? ์ €ํฌ ์ˆ™๋ จ๋œ ๊ณผํ•™์ž ํŒ€์ด ๋„์™€๋“œ๋ฆฌ๊ฒ ์Šต๋‹ˆ๋‹ค.
๋„์›€ ๋ฌธ์˜
๊ธฐ์ˆ  ์„œ๋น„์Šค
๋„์›€์ด ํ•„์š”ํ•˜์‹ ๊ฐ€์š”? ์ €ํฌ ์ˆ™๋ จ๋œ ๊ณผํ•™์ž ํŒ€์ด ๋„์™€๋“œ๋ฆฌ๊ฒ ์Šต๋‹ˆ๋‹ค.
๋„์›€ ๋ฌธ์˜

InChI key

YEZNLOUZAIOMLT-UHFFFAOYSA-N

InChI

1S/C14H12ClNO2/c1-9-11(15)6-4-8-12(9)16-13-7-3-2-5-10(13)14(17)18/h2-8,16H,1H3,(H,17,18)

SMILES string

Cc1c(Cl)cccc1Nc2ccccc2C(O)=O

assay

≥98% (TLC)

form

powder

solubility

ethanol: 50 mg/mL, clear, greenish-yellow

Quality Level

์œ ์‚ฌํ•œ ์ œํ’ˆ์„ ์ฐพ์œผ์‹ญ๋‹ˆ๊นŒ? ๋ฐฉ๋ฌธ ์ œํ’ˆ ๋น„๊ต ์•ˆ๋‚ด

General description

Tolfenamic acid is a fenamate and is made up of a monocarboxylate diphenylamine nucleus.

Application

Tolfenamic acid has been used in Arabidopsisย bud assay for activity comparison with quinazolinedione derivatives (QADD) based compounds.

Biochem/physiol Actions

Non-steroidal anti-inflammatory agent. Interferes with synthesis of ฮฒ-amyloid precursor protein, and thus Aฮฒ peptides, by promoting degradation of an essential transcription factor.
Tolfenamic acid is involved in the inhibition of prostaglandin synthesis. It also plays a role in apoptosis of head and neck cancer cells.

pictograms

Skull and crossbones

signalword

Danger

hcodes

Hazard Classifications

Acute Tox. 3 Oral

์ €์žฅ ๋“ฑ๊ธ‰

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves


๊ฐ€์žฅ ์ตœ์‹  ๋ฒ„์ „ ์ค‘ ํ•˜๋‚˜๋ฅผ ์„ ํƒํ•˜์„ธ์š”:

์‹œํ—˜ ์„ฑ์ ์„œ(COA)

Lot/Batch Number

์ ํ•ฉํ•œ ๋ฒ„์ „์„ ์ฐพ์„ ์ˆ˜ ์—†์œผ์‹ ๊ฐ€์š”?

ํŠน์ • ๋ฒ„์ „์ด ํ•„์š”ํ•œ ๊ฒฝ์šฐ ๋กœํŠธ ๋ฒˆํ˜ธ๋‚˜ ๋ฐฐ์น˜ ๋ฒˆํ˜ธ๋กœ ํŠน์ • ์ธ์ฆ์„œ๋ฅผ ์ฐพ์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

์ด ์ œํ’ˆ์„ ์ด๋ฏธ ๊ฐ€์ง€๊ณ  ๊ณ„์‹ญ๋‹ˆ๊นŒ?

๋ฌธ์„œ ๋ผ์ด๋ธŒ๋Ÿฌ๋ฆฌ์—์„œ ์ตœ๊ทผ์— ๊ตฌ๋งคํ•œ ์ œํ’ˆ์— ๋Œ€ํ•œ ๋ฌธ์„œ๋ฅผ ์ฐพ์•„๋ณด์„ธ์š”.

๋ฌธ์„œ ๋ผ์ด๋ธŒ๋Ÿฌ๋ฆฌ ๋ฐฉ๋ฌธ

Vilmalรญ Lรณpez-Mejรญas et al.
Journal of the American Chemical Society, 131(13), 4554-4555 (2009-04-02)
The nonsteroidal anti-inflammatory drug (NSAID) tolfenamic acid (TA), previously thought to be dimorphic, is demonstrated to have at least five polymorphs. The new forms were uncovered through the emerging screening technique of polymer-induced heteronucleation (PIHn). The presence of conformational changes
Polymer-induced heteronucleation of tolfenamic acid: structural investigation of a pentamorph
Lopez M V, et al.
Journal of the American Chemical Society, 131(13), 4554-4555 (2009)
Chemical synthesis and characterization of a new quinazolinedione competitive antagonist for strigolactone receptors with an unexpected binding mode
Hamiaux C, et al.
The Biochemical Journal, 476(12), 1843-1856 (2019)
R A Tokola et al.
Cephalalgia : an international journal of headache, 4(4), 253-263 (1984-12-01)
Tolfenamic acid is a fenamate which inhibits prostaglandin (PG) biosynthesis and may act as a PG antagonist as well. Caffeine and metoclopramide are used in combination with analgesics and ergotamine in the treatment of migraine attacks, but controlled clinical studies
Umesh T Sankpal et al.
The Prostate, 72(15), 1648-1658 (2012-04-05)
Specificity protein (Sp) transcription factors are implicated in critical cellular and molecular processes associated with cancer that impact tumor growth and metastasis. The non-steroidal anti-inflammatory drug, tolfenamic acid (TA) is known to inhibit Sp proteins in some human cancer cells

์ž์‚ฌ์˜ ๊ณผํ•™์žํŒ€์€ ์ƒ๋ช… ๊ณผํ•™, ์žฌ๋ฃŒ ๊ณผํ•™, ํ™”ํ•™ ํ•ฉ์„ฑ, ํฌ๋กœ๋งˆํ† ๊ทธ๋ž˜ํ”ผ, ๋ถ„์„ ๋ฐ ๊ธฐํƒ€ ๋งŽ์€ ์˜์—ญ์„ ํฌํ•จํ•œ ๋ชจ๋“  ๊ณผํ•™ ๋ถ„์•ผ์— ๊ฒฝํ—˜์ด ์žˆ์Šต๋‹ˆ๋‹ค..

๊ณ ๊ฐ์ง€์›ํŒ€์œผ๋กœ ์—ฐ๋ฝ๋ฐ”๋ž๋‹ˆ๋‹ค.